Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Abeona Therapeutics (ABEO) Enterprise Value: 2011-2025

Historic Enterprise Value for Abeona Therapeutics (ABEO) over the last 15 years, with Sep 2025 value amounting to $63.3 million.

  • Abeona Therapeutics' Enterprise Value fell 61.34% to $63.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$413.3 million, marking a year-over-year decrease of 454.19%. This contributed to the annual value of $144.1 million for FY2024, which is 101.36% up from last year.
  • Abeona Therapeutics' Enterprise Value amounted to $63.3 million in Q3 2025, which was down 2.19% from $64.7 million recorded in Q2 2025.
  • In the past 5 years, Abeona Therapeutics' Enterprise Value ranged from a high of $163.7 million in Q3 2024 and a low of -$16.6 million during Q4 2021.
  • Its 3-year average for Enterprise Value is $79.2 million, with a median of $64.7 million in 2025.
  • Its Enterprise Value has fluctuated over the past 5 years, first slumped by 128.24% in 2021, then spiked by 17,163.46% in 2023.
  • Quarterly analysis of 5 years shows Abeona Therapeutics' Enterprise Value stood at -$16.6 million in 2021, then surged by 102.50% to $414,461 in 2022, then surged by 17,163.46% to $71.6 million in 2023, then skyrocketed by 101.36% to $144.1 million in 2024, then crashed by 61.34% to $63.3 million in 2025.
  • Its last three reported values are $63.3 million in Q3 2025, $64.7 million for Q2 2025, and $78.3 million during Q1 2025.